JP2001517425A5 - - Google Patents

Download PDF

Info

Publication number
JP2001517425A5
JP2001517425A5 JP2000512857A JP2000512857A JP2001517425A5 JP 2001517425 A5 JP2001517425 A5 JP 2001517425A5 JP 2000512857 A JP2000512857 A JP 2000512857A JP 2000512857 A JP2000512857 A JP 2000512857A JP 2001517425 A5 JP2001517425 A5 JP 2001517425A5
Authority
JP
Japan
Prior art keywords
cells
kda
lymphocytes
activated
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000512857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001517425A (ja
JP4463418B2 (ja
Filing date
Publication date
Priority claimed from DE19821060A external-priority patent/DE19821060A1/de
Application filed filed Critical
Priority claimed from PCT/DE1998/002896 external-priority patent/WO1999015553A2/de
Publication of JP2001517425A publication Critical patent/JP2001517425A/ja
Publication of JP2001517425A5 publication Critical patent/JP2001517425A5/ja
Application granted granted Critical
Publication of JP4463418B2 publication Critical patent/JP4463418B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000512857A 1997-09-23 1998-09-23 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 Expired - Fee Related JP4463418B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19741929 1997-09-23
DE19741929.1 1997-09-23
DE19821060.4 1998-05-11
DE19821060A DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
PCT/DE1998/002896 WO1999015553A2 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009211970A Division JP5021008B2 (ja) 1997-09-23 2009-09-14 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用

Publications (3)

Publication Number Publication Date
JP2001517425A JP2001517425A (ja) 2001-10-09
JP2001517425A5 true JP2001517425A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4463418B2 JP4463418B2 (ja) 2010-05-19

Family

ID=26040229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000512857A Expired - Fee Related JP4463418B2 (ja) 1997-09-23 1998-09-23 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用

Country Status (8)

Country Link
US (2) US7259247B1 (cg-RX-API-DMAC7.html)
EP (1) EP1017723B1 (cg-RX-API-DMAC7.html)
JP (1) JP4463418B2 (cg-RX-API-DMAC7.html)
AU (1) AU752433B2 (cg-RX-API-DMAC7.html)
CA (1) CA2305350C (cg-RX-API-DMAC7.html)
DE (1) DE59813875D1 (cg-RX-API-DMAC7.html)
ES (1) ES2279585T3 (cg-RX-API-DMAC7.html)
WO (1) WO1999015553A2 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
JP4463418B2 (ja) 1997-09-23 2010-05-19 ドイツ連邦共和国 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
EP2332976B1 (en) * 1999-02-03 2014-04-02 Amgen, Inc Novel polypeptides involved in immune response
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
WO2001012658A2 (en) * 1999-08-11 2001-02-22 Isis Innovations Limited Human icos ligand and application thereof
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
EP1900816A3 (en) * 1999-09-21 2008-03-26 Genetics Institute, LLC GL50 molecules and uses therefor
EP1218504B1 (en) 1999-09-21 2007-07-11 Genetics Institute, LLC Gl50 molecules and uses therefor
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
EP2042596B1 (en) * 2000-11-28 2015-02-11 Amgen Inc. Polypeptides involved in immune response
WO2002074803A2 (en) * 2001-01-16 2002-09-26 Bayer Aktiengesellschaft Regulation of human icos v protein
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
KR102023661B1 (ko) 2011-03-31 2019-09-23 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Icos에 대한 항체 및 이의 용도
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
RS60538B1 (sr) 2013-03-15 2020-08-31 Glaxosmithkline Ip Dev Ltd Anti-lag-3 vezujući proteini
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
RU2760582C2 (ru) 2015-09-02 2021-11-29 Иммутеп С.А.С. Анти-LAG-3 антитела
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル-マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
UA129038C2 (uk) 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型cdcp1に対する抗体およびその使用
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) * 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
KR900702370A (ko) * 1988-10-06 1990-12-06 제임스 디. 그랜트 가용성 t세포 표면분자를 사용하는 치료 및 진단방법
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP4463418B2 (ja) 1997-09-23 2010-05-19 ドイツ連邦共和国 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用

Similar Documents

Publication Publication Date Title
JP2010042007A5 (cg-RX-API-DMAC7.html)
Singer et al. CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells
Murai et al. Active participation of CCR5+ CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease
Auerbach et al. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor
Uppaluri et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody
Riley et al. Naıve and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implications for transmission and pathogenesis
Montefiori et al. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
Odobasic et al. Distinct in vivo roles of CD80 and CD86 in the effector T‐cell responses inducing antigen‐induced arthritis
Dobloug et al. Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis.
CA2011893A1 (en) Pharmaceutical product for the treatment of immunoregulatory disorders
JP2001517425A (ja) T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
Cuthbert et al. Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy
Kleinau et al. Oil-induced arthritis in DA rats passive transfer by T cells but not with serum
Müller‐Ladner et al. Progressive joint destruction in a human immunodeficiency virus‐infected patient with rheumatoid arthritis
Lehner et al. Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques
Speth et al. Complement receptors in HIV infection
Zeiser Biology-driven developments in the therapy of acute graft-versus-host disease
Vermeire et al. Specific CD4 down-modulating compounds with potent anti-HIV activity
WO1995007716A1 (en) Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
Tanaka et al. Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection
Starling et al. Inhibition of natural killer-cell mediated cytolysis with monoclonal antibodies to restricted and non-restricted epitopes of the leucocyte common antigen
CA2377479C (en) Compositions and methods for preventing transepithelial transmission of hiv
Molet et al. Modulation of cell adhesion molecules on human endothelial cells by eosinophil-derived mediators
Saha et al. Resistance against syncytium-inducing human immunodeficiency virus type 1 (HIV-1) in selected CD4+ T cells from an HIV-1-infected nonprogressor: evidence of a novel pathway of resistance mediated by a soluble factor (s) that acts after virus entry
Palacios et al. The alpha chain, not the beta chain of HLA-DR antigens participates in activation of T cells in autologous mixed lymphocyte reaction